MarketCap
Facebook
X
TelegramKadmon Holdings, Inc. P/S Ratio 2011-2026 | KDMN
Annual P/S Ratio Kadmon Holdings, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 98.1 | 119 | 159 | 26.1 | 3.43 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 | 3.43 | 81 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M |  Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
11 | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
I-Mab
IMAB
|
94.1 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B |  France |
 |
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | USA |
 |
BioNTech SE
BNTX
|
35.7 | $ 91.28 | 0.11 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
8.94 | - | - | $ 2.17 B | USA |
 |
Aquestive Therapeutics
AQST
|
10.5 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
2.65 | $ 8.22 | 2.37 % | $ 225 M |  Israel |
 |
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
2.17 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
1.32 K | $ 31.37 | 1.0 % | $ 2.08 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
9.15 | $ 23.66 | 0.11 % | $ 3.01 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
2.27 | - | - | $ 546 M | USA |
 |
Brickell Biotech
BBI
|
1.42 | - | -5.38 % | $ 6.06 M | USA |
 |
Ardelyx
ARDX
|
3.98 | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
CASI Pharmaceuticals
CASI
|
36.1 | - | - | $ 35.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
106 | - | -11.43 % | $ 502 K | USA |
 |
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | USA |
 |
argenx SE
ARGX
|
311 | $ 748.25 | 0.25 % | $ 25 B |  Niderland |